Despite promising preclinical studies with innate agonists as potential immunotherapeutics or vaccine adjuvants [1], these agents such as STING [2] and NLRP3 [3] agonists have not been tested in most of the tumor types [4] for efficacy due to the difficulties associated with their intratumoral delivery. This evidence concerns the gene STING1 and neoplasm.